Botulinum toxin for masseter hypertrophy

Fedorowicz, Zbys; Al‐Muharraqi, Mohammed A; Bareeq, Jaffer Al; Bareeq, Reem Al; Nasser, Mona

doi:10.1002/14651858.cd007510

Cited by 5 publications

(10 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cosmetic sculpturing of the lower face using botulinum toxin has been accepted as an effective and safe alternative to invasive surgical managements [2]. However, no single conversion ratio exists between different serotypes of the toxin [12] nor have there been any comparative split-face trials using BTX-A and BTX-B for the treatment of masseter hypertrophy.…”

Section: Discussionmentioning

confidence: 99%

“…CT scanning, considered to be the gold standard in confirming a clinical suspicion of masseter hypertrophy [2], showed a 21-30% volume reduction with BTX-A (Botox and Dysport) at 12 weeks post-treatment [6,13]. In this study, masseter volume was calculated by the reconstruction of 1-mm-thick cross-sectioned CT images in order to improve the precision and reliability of the post-treatment evaluations.…”

Section: Discussionmentioning

confidence: 99%

“…Masseter hypertrophy, resulting in a so-called square face, is characterized by a unilateral or bilateral benign enlargement of the masseter muscles and is frequent in Asians, occurring in association with ethnic differences and mastication habits [2]. As Asian women do not consider this condition aesthetically pleasing, there is a steady demand to create a slimmer profile of the lower face, achieved through mandibular contouring carried out either surgically or non-surgically.…”

Section: Introductionmentioning

confidence: 99%

“…Surgical treatments, such as ostectomy, neurectomy or masseter muscle resection, pose a risk of bleeding, hematoma, persistent swelling and facial nerve injury. Non-surgical options include pharmacotherapy in the form of muscle relaxants, dental restoration and occlusal adjustments, albeit with limited degrees of success [2]. In the mid-1990s, a novel, off-label non-surgical approach using botulinum toxin was introduced [3].…”

Section: Introductionmentioning

confidence: 99%

“…In the mid-1990s, a novel, off-label non-surgical approach using botulinum toxin was introduced [3]. The technique quickly became widespread due to its efficacy and safety [2]. According to the literature, 30 U of OnabotulinumtoxinA (BTX-A; Botox®, Allergan Inc., Irvine, Calif., USA) is effective in the treatment of masseter hypertrophy [4,5,6].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

RimabotulinumtoxinB versus OnabotulinumtoxinA in the Treatment of Masseter Hypertrophy: A 24-Week Double-Blind Randomized Split-Face Study

et al. 2013

View full text Add to dashboard Cite

Background: Masseter hypertrophy can be ameliorated by botulinum toxin. Objective: To compare the efficacy and safety of RimabotulinumtoxinB (BTX-B) and OnabotulinumtoxinA (BTX-A) in the treatment of masseter hypertrophy. Methods: Sixteen women with bilateral masseter hypertrophy received single injections of BTX-A or BTX-B at a dose ratio of 1:50 or 1:70 in a 24-week double-blind randomized split-face study. Results: Both BTX-A and BTX-B produced significant improvements in masseter hypertrophy. The maximum volume reduction, as determined by computed tomography scanning, at week 12 was comparable between BTX-A and BTX-B at a dose ratio of 1:70 (15.6 and 14.2%, respectively). At week 24, only masseters treated with BTX-A maintained a significant volume reduction. Investigator ratings and patient satisfaction scores paralleled objective computed tomography measurements. Conclusion: Both BTX-A and BTX-B are effective in the treatment of masseter hypertrophy. BTX-B, at a dose ratio of 1:70, has a comparable efficacy but a shorter duration of action than BTX-A.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

RimabotulinumtoxinB versus OnabotulinumtoxinA in the Treatment of Masseter Hypertrophy: A 24-Week Double-Blind Randomized Split-Face Study

et al. 2013

View full text Add to dashboard Cite

show abstract

Bone and cartilage changes in rabbit mandibular condyles after 1 injection of botulinum toxin

Matthys

Dang

Rafferty

et al. 2015

American Journal of Orthodontics and Dentofacial Orthopedics

View full text Add to dashboard Cite

Introduction Temporary paralysis of the masseter muscle using botulinum toxin is a common treatment for temporomandibular disorders, bruxism, and muscle hypertrophy. Loss of masseter force is associated with decreased mandibular mineral density. Our objectives were (1) to establish whether bone loss at the mandibular condyle is regionally specific, and (2) to ascertain whether the treatment affects the condylar cartilage. Methods Young adult female rabbits received a unilateral masseter injection of botulinum neurotoxin serotype A (BoNT/A, n=31), saline (n=19) or no injection (n=3) and were also injected with bromodeoxyuridine (BrdU), a replication marker. Termination occurred 4 or 12 weeks following treatment. Condyles were processed by paraffin histology. Cortical thickness, cartilage thickness and trabecular bone areal density were measured, and replicating cells were counted after BrdU reaction. Results BoNT/A rabbits exhibited a high frequency of defects in the condylar bone surface, occurring equally on injected and uninjected sides. Bone loss was seen only on the side of the BoNT/A injection. Cortical as well as trabecular bone was severely affected. The midcondylar region lost the most bone. Recovery at 12 weeks was insignificant. Condylar cartilage thickness showed no treatment effect but did increase with time. Numbers of proliferating cells were similar in treatment groups, but BoNT/A animals showed more side asymmetry in association with the condylar defects. Conclusion Bone loss may be a risk factor for the use of botulinum toxin in jaw muscles.

show abstract

Knowledge Gaps in Oral and Maxillofacial Surgery: A Systematic Mapping

Österberg

Holmlund

Sunzel

et al. 2017

Int J Technol Assess Health Care

View full text Add to dashboard Cite

show abstract

Botulinum toxin for masseter hypertrophy

Abstract: Cochrane Database of Systematic Reviews Main resultsWe retrieved 683 unique references to studies. A er screening these references 660 were excluded for being non-applicable. We assessed 23 full text articles for eligibility and all of these studies were excluded from the review.

Cited by 5 publications

References 15 publications

RimabotulinumtoxinB versus OnabotulinumtoxinA in the Treatment of Masseter Hypertrophy: A 24-Week Double-Blind Randomized Split-Face Study

RimabotulinumtoxinB versus OnabotulinumtoxinA in the Treatment of Masseter Hypertrophy: A 24-Week Double-Blind Randomized Split-Face Study

Bone and cartilage changes in rabbit mandibular condyles after 1 injection of botulinum toxin

Knowledge Gaps in Oral and Maxillofacial Surgery: A Systematic Mapping

Contact Info

Product

Resources

About